U.S. Tardive Dyskinesia Therapeutics Market

U.S. Tardive Dyskinesia Therapeutics Market Size, Share, Growth Analysis, By Drug(Deutetrabenazine, Valbenazine), By Distribution Channel(Hospital Pharmacies, Drug Stores & Retail Pharmacies), By Region/Country(Northeast, Southeast) - Industry Forecast 2024-2031


Report ID: UCMIR35I2281 | Region: Regional | Published Date: Upcoming |
Pages: 165 | Tables: 55 | Figures: 60

U.S. Tardive Dyskinesia Therapeutics Market Insights

Market Overview:

The market for treating tardive dyskinesia in the United States was valued at USD 2.24 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 7.8% throughout the forecasted period. There has been a notable rise in Tardive Dyskinesia (TD) awareness among patients in the U.S., a movement disorder that arises as a side effect of prolonged antipsychotic usage. The Gerontological Advanced Practice Nurses Association (GAPNA) conducted a TD therapeutics awareness initiative from May 1st to May 7th, 2022, promoting knowledge and understanding of the condition.

U.S. Tardive Dyskinesia Therapeutics Market, Forecast & Y-O-Y Growth Rate, 2020 - 2028
ForecastGrowthRate
To get more reports on the above market click here to
Get Free Sample

This report is being written to illustrate the market opportunity by region and by segments, indicating opportunity areas for the vendors to tap upon. To estimate the opportunity, it was very important to understand the current market scenario and the way it will grow in future.

Production and consumption patterns are being carefully compared to forecast the market. Other factors considered to forecast the market are the growth of the adjacent market, revenue growth of the key market vendors, scenario-based analysis, and market segment growth.

The market size was determined by estimating the market through a top-down and bottom-up approach, which was further validated with industry interviews. Considering the nature of the market we derived the Pharmaceuticals by segment aggregation, the contribution of the Pharmaceuticals in Pharmaceuticals, Biotechnology & Life Sciences and vendor share.

To determine the growth of the market factors such as drivers, trends, restraints, and opportunities were identified, and the impact of these factors was analyzed to determine the market growth. To understand the market growth in detail, we have analyzed the year-on-year growth of the market. Also, historic growth rates were compared to determine growth patterns.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The market for U.S. Tardive Dyskinesia Therapeutics was estimated to be valued at US$ XX Mn in 2021.

The U.S. Tardive Dyskinesia Therapeutics Market is estimated to grow at a CAGR of XX% by 2028.

The U.S. Tardive Dyskinesia Therapeutics Market is segmented on the basis of Drug, Distribution Channel, Region/Country.

Based on region, the U.S. Tardive Dyskinesia Therapeutics Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the U.S. Tardive Dyskinesia Therapeutics Market are , Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group Corporation) , Teva Pharmaceutical Industries Ltd. , Neurocrine Biosciences, Inc. , SOM BIOTECH , Luye Pharma Group .

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

U.S. Tardive Dyskinesia Therapeutics Market

Product ID: UCMIR35I2281

$5,300
BUY NOW GET FREE SAMPLE